Effects and safety of GLP-1 receptor drugs in kidney transplant patients with diabetes after transplant
Updated
Abstract
The efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in kidney transplant recipients with post-transplant diabetes mellitus is being assessed.
- GLP-1 RAs may improve glycemic control in kidney transplant recipients with post-transplant diabetes mellitus.
- The safety profile of GLP-1 RAs in this population is under investigation.
- Post-transplant diabetes mellitus is a common complication in kidney transplant recipients.
Simplified